BridgeBio Pharma SG&A Expenses 2018-2024 | BBIO

BridgeBio Pharma sg&a expenses for the twelve months ending June 30, 2024 were $0.209B, a 60.19% increase year-over-year.

  • BridgeBio Pharma annual sg&a expenses for 2023 were $0.151B, a 5.17% increase from 2022.
  • BridgeBio Pharma annual sg&a expenses for 2022 were $0.143B, a 25.5% decline from 2021.
  • BridgeBio Pharma annual sg&a expenses for 2021 were $0.192B, a 31.94% increase from 2020.

BridgeBio Pharma SG&A Expenses 2018-2024 | BBIO

  • BridgeBio Pharma annual sg&a expenses for 2023 were $0.151B, a 5.17% increase from 2022.
  • BridgeBio Pharma annual sg&a expenses for 2022 were $0.143B, a 25.5% decline from 2021.
  • BridgeBio Pharma annual sg&a expenses for 2021 were $0.192B, a 31.94% increase from 2020.
Related Stocks
Company NameMarket
Cap
Teva Pharmaceutical Industries (TEVA)$20.1B
Dr Reddy's Laboratories (RDY)$13.1B
Bausch Health Cos (BHC)$3B
Amphastar Pharmaceuticals (AMPH)$2.4B
Supernus Pharmaceuticals (SUPN)$1.8B
Taysha Gene Therapies (TSHA)$449M
Personalis (PSNL)$315M
Assembly Biosciences (ASMB)$117M
Acasti Pharma (ACST)$28M
Sol-Gel Technologies (SLGL)$20M
Evoke Pharma (EVOK)$4M
Teligent (TLGT)$0M